Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 75 entries
Sorted by: Best Match Show Resources per page
Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

Translational lung cancer research

Komiya T, Yamamoto S, Roy A, McDonald P, Perez RP.
PMID: 29114475
Transl Lung Cancer Res. 2017 Oct;6(5):600-610. doi: 10.21037/tlcr.2017.07.02.

BACKGROUND: Our previous study suggested NR4A2, a subfamily member of orphan nuclear receptors, is essential for survival of human cancer cells such as mucoepidermoid carcinoma (MEC).METHODS: We conducted high throughput drug screening for NR4A2 inhibitors as a novel therapeutic...

Cite
Komiya T, Yamamoto S, Roy A, et al. Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. Transl Lung Cancer Res. 2017;6(5):600-610doi: 10.21037/tlcr.2017.07.02.
Komiya, T., Yamamoto, S., Roy, A., McDonald, P., & Perez, R. P. (2017). Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. Translational lung cancer research, 6(5), 600-610. https://doi.org/10.21037/tlcr.2017.07.02
Komiya, Takefumi, et al. "Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics." Translational lung cancer research vol. 6,5 (2017): 600-610. doi: https://doi.org/10.21037/tlcr.2017.07.02
Komiya T, Yamamoto S, Roy A, McDonald P, Perez RP. Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. Transl Lung Cancer Res. 2017 Oct;6(5):600-610. doi: 10.21037/tlcr.2017.07.02. PMID: 29114475; PMCID: PMC5653521.
Copy Download .nbib Format: NLM
An updated h-index measures both the primary and total scientific output of a researcher.

Discoveries (Craiova, Romania)

Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA.
PMID: 26504901
Discoveries (Craiova). 2015 Jul-Sep;3(3). doi: 10.15190/d.2015.42. Epub 2015 Sep 30.

The growing interest in scientometry stems from ethical concerns related to the proper evaluation of scientific contributions of an author working in a hard science. In the absence of a consensus, institutions may use arbitrary methods for evaluating scientists...

Cite
Bucur O, Almasan A, Zubarev R, et al. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015;3(3)doi: 10.15190/d.2015.42.
Bucur, O., Almasan, A., Zubarev, R., Friedman, M., Nicolson, G. L., Sumazin, P., Leabu, M., Nikolajczyk, B. S., Avram, D., Kunej, T., Calin, G. A., Godwin, A. K., Adami, H. O., Zaphiropoulos, P. G., Richardson, D. R., Schmitt-Ulms, G., Westerblad, H., Keniry, M., Grau, G. E., Carbonetto, S., Stan, R. V., Popa-Wagner, A., Takhar, K., Baron, B. W., Galardy, P. J., Yang, F., Data, D., Fadare, O., Yeo, K. J., Gabreanu, G. R., Andrei, S., Soare, G. R., Nelson, M. A., & Liehn, E. A. (2015). An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova, Romania), 3(3), . https://doi.org/10.15190/d.2015.42
Bucur, Octavian, et al. "An updated h-index measures both the primary and total scientific output of a researcher." Discoveries (Craiova, Romania) vol. 3,3 (2015). doi: https://doi.org/10.15190/d.2015.42
Bucur O, Almasan A, Zubarev R, Friedman M, Nicolson GL, Sumazin P, Leabu M, Nikolajczyk BS, Avram D, Kunej T, Calin GA, Godwin AK, Adami HO, Zaphiropoulos PG, Richardson DR, Schmitt-Ulms G, Westerblad H, Keniry M, Grau GE, Carbonetto S, Stan RV, Popa-Wagner A, Takhar K, Baron BW, Galardy PJ, Yang F, Data D, Fadare O, Yeo KJ, Gabreanu GR, Andrei S, Soare GR, Nelson MA, Liehn EA. An updated h-index measures both the primary and total scientific output of a researcher. Discoveries (Craiova). 2015 Jul-Sep;3(3). doi: 10.15190/d.2015.42. Epub 2015 Sep 30. PMID: 26504901; PMCID: PMC4617786.
Copy Download .nbib Format: NLM
Histone Demethylases in Colon Cancer.

Current colorectal cancer reports

Paul S, Ramalingam S, Subramaniam D, Baranda J, Anant S, Dhar A.
PMID: 25574158
Curr Colorectal Cancer Rep. 2014 Dec 01;10(4):417-424. doi: 10.1007/s11888-014-0253-2.

Cell growth and proliferation are controlled through different posttranslational modifications including demethylation, a process regulated by regulated by the demethylase enzymes. This review focuses on our current understanding of functional and therapeutic potentials of histone demethylases in colon cancer....

Cite
Paul S, Ramalingam S, Subramaniam D, et al. Histone Demethylases in Colon Cancer. Curr Colorectal Cancer Rep. 2014;10(4):417-424doi: 10.1007/s11888-014-0253-2.
Paul, S., Ramalingam, S., Subramaniam, D., Baranda, J., Anant, S., & Dhar, A. (2014). Histone Demethylases in Colon Cancer. Current colorectal cancer reports, 10(4), 417-424. https://doi.org/10.1007/s11888-014-0253-2
Paul, Santanu, et al. "Histone Demethylases in Colon Cancer." Current colorectal cancer reports vol. 10,4 (2014): 417-424. doi: https://doi.org/10.1007/s11888-014-0253-2
Paul S, Ramalingam S, Subramaniam D, Baranda J, Anant S, Dhar A. Histone Demethylases in Colon Cancer. Curr Colorectal Cancer Rep. 2014 Dec 01;10(4):417-424. doi: 10.1007/s11888-014-0253-2. PMID: 25574158; PMCID: PMC4283932.
Copy Download .nbib Format: NLM
Cancer Stem Cell Metabolism and Potential Therapeutic Targets.

Frontiers in oncology

Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S.
PMID: 29922594
Front Oncol. 2018 Jun 05;8:203. doi: 10.3389/fonc.2018.00203. eCollection 2018.

Malignant tumors contain heterogeneous populations of cells in various states of proliferation and differentiation. The presence of cancer stem or initiating cells is a well-established concept wherein quiescent and poorly differentiated cells within a tumor mass contribute to drug...

Cite
Snyder V, Reed-Newman TC, Arnold L, et al. Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol. 2018;8:203doi: 10.3389/fonc.2018.00203.
Snyder, V., Reed-Newman, T. C., Arnold, L., Thomas, S. M., & Anant, S. (2018). Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Frontiers in oncology, 8203. https://doi.org/10.3389/fonc.2018.00203
Snyder, Vusala, et al. "Cancer Stem Cell Metabolism and Potential Therapeutic Targets." Frontiers in oncology vol. 8 (2018): 203. doi: https://doi.org/10.3389/fonc.2018.00203
Snyder V, Reed-Newman TC, Arnold L, Thomas SM, Anant S. Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol. 2018 Jun 05;8:203. doi: 10.3389/fonc.2018.00203. eCollection 2018. PMID: 29922594; PMCID: PMC5996058.
Copy Download .nbib Format: NLM
MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.

Oncotarget

Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T.
PMID: 29765550
Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and the prognosis of HCC patients, especially those with metastasis, remains extremely poor. This is partly due to unclear molecular mechanisms underlying HCC metastasis. Our previous study indicates...

Cite
Ranjan A, Iyer SV, Ward C, et al. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018;9(30):21429-21443doi: 10.18632/oncotarget.25117.
Ranjan, A., Iyer, S. V., Ward, C., Link, T., Diaz, F. J., Dhar, A., Tawfik, O. W., Weinman, S. A., Azuma, Y., Izumi, T., & Iwakuma, T. (2018). MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget, 9(30), 21429-21443. https://doi.org/10.18632/oncotarget.25117
Ranjan, Atul, et al. "MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma." Oncotarget vol. 9,30 (2018): 21429-21443. doi: https://doi.org/10.18632/oncotarget.25117
Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20. PMID: 29765550; PMCID: PMC5940416.
Copy Download .nbib Format: NLM
Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.

Cancer letters

Provance OK, Geanes ES, Lui AJ, Roy A, Holloran SM, Gunewardena S, Hagan CR, Weir S, Lewis-Wambi J.
PMID: 34022283
Cancer Lett. 2021 Aug 28;514:12-29. doi: 10.1016/j.canlet.2021.05.006. Epub 2021 May 20.

Overexpression of interferon induced transmembrane protein-1 (IFITM1) enhances tumor progression in multiple cancers, but its role in triple-negative breast cancer (TNBC) is unknown. Here, we explore the functional significance and regulation of IFITM1 in TNBC and strategies to target...

Cite
Provance OK, Geanes ES, Lui AJ, et al. Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer Lett. 2021;514:12-29doi: 10.1016/j.canlet.2021.05.006.
Provance, O. K., Geanes, E. S., Lui, A. J., Roy, A., Holloran, S. M., Gunewardena, S., Hagan, C. R., Weir, S., & Lewis-Wambi, J. (2021). Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer letters, 51412-29. https://doi.org/10.1016/j.canlet.2021.05.006
Provance, Olivia K, et al. "Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression." Cancer letters vol. 514 (2021): 12-29. doi: https://doi.org/10.1016/j.canlet.2021.05.006
Provance OK, Geanes ES, Lui AJ, Roy A, Holloran SM, Gunewardena S, Hagan CR, Weir S, Lewis-Wambi J. Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer Lett. 2021 Aug 28;514:12-29. doi: 10.1016/j.canlet.2021.05.006. Epub 2021 May 20. PMID: 34022283; PMCID: PMC8221017.
Copy Download .nbib Format: NLM
Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study.

Nutrition and cancer

Hamilton-Reeves JM, Johnson CN, Hand LK, Bechtel MD, Robertson HL, Michel C, Metcalf M, Chalise P, Mahan NJ, Mirza M, Lee EK, Sullivan DK, Klemp JR, Befort CA, Parker WP, Gibbs HD, Demark-Wahnefried W, Thrasher JB.
PMID: 33295204
Nutr Cancer. 2021;73(11):2671-2686. doi: 10.1080/01635581.2020.1856890. Epub 2020 Dec 09.

BACKGROUND: Overweight men with prostate cancer are more likely to suffer from recurrence and death following prostatectomy compared with healthy weight men. This study tested the feasibility of delivering a comprehensive program to foster weight loss before and weight...

Cite
Hamilton-Reeves JM, Johnson CN, Hand LK, et al. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutr Cancer. 2020;73(11):2671-2686doi: 10.1080/01635581.2020.1856890.
Hamilton-Reeves, J. M., Johnson, C. N., Hand, L. K., Bechtel, M. D., Robertson, H. L., Michel, C., Metcalf, M., Chalise, P., Mahan, N. J., Mirza, M., Lee, E. K., Sullivan, D. K., Klemp, J. R., Befort, C. A., Parker, W. P., Gibbs, H. D., Demark-Wahnefried, W., & Thrasher, J. B. (2021). Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutrition and cancer, 73(11), 2671-2686. https://doi.org/10.1080/01635581.2020.1856890
Hamilton-Reeves, Jill M, et al. "Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study." Nutrition and cancer vol. 73,11 (2021): 2671-2686. doi: https://doi.org/10.1080/01635581.2020.1856890
Hamilton-Reeves JM, Johnson CN, Hand LK, Bechtel MD, Robertson HL, Michel C, Metcalf M, Chalise P, Mahan NJ, Mirza M, Lee EK, Sullivan DK, Klemp JR, Befort CA, Parker WP, Gibbs HD, Demark-Wahnefried W, Thrasher JB. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study. Nutr Cancer. 2021;73(11):2671-2686. doi: 10.1080/01635581.2020.1856890. Epub 2020 Dec 09. PMID: 33295204; PMCID: PMC8371995.
Copy Download .nbib Format: NLM
Mechanisms of breast cancer metastasis.

Clinical & experimental metastasis

Nathanson SD, Detmar M, Padera TP, Yates LR, Welch DR, Beadnell TC, Scheid AD, Wrenn ED, Cheung K.
PMID: 33950409
Clin Exp Metastasis. 2021 May 05; doi: 10.1007/s10585-021-10090-2. Epub 2021 May 05.

Invasive breast cancer tends to metastasize to lymph nodes and systemic sites. The management of metastasis has evolved by focusing on controlling the growth of the disease in the breast/chest wall, and at metastatic sites, initially by surgery alone,...

Cite
Nathanson SD, Detmar M, Padera TP, et al. Mechanisms of breast cancer metastasis. Clin Exp Metastasis. 2021;doi: 10.1007/s10585-021-10090-2.
Nathanson, S. D., Detmar, M., Padera, T. P., Yates, L. R., Welch, D. R., Beadnell, T. C., Scheid, A. D., Wrenn, E. D., & Cheung, K. (2021). Mechanisms of breast cancer metastasis. Clinical & experimental metastasis, . https://doi.org/10.1007/s10585-021-10090-2
Nathanson, S David, et al. "Mechanisms of breast cancer metastasis." Clinical & experimental metastasis vol. (2021). doi: https://doi.org/10.1007/s10585-021-10090-2
Nathanson SD, Detmar M, Padera TP, Yates LR, Welch DR, Beadnell TC, Scheid AD, Wrenn ED, Cheung K. Mechanisms of breast cancer metastasis. Clin Exp Metastasis. 2021 May 05; doi: 10.1007/s10585-021-10090-2. Epub 2021 May 05. PMID: 33950409; PMCID: PMC8568733.
Copy Download .nbib Format: NLM
DNAJA1 promotes cancer metastasis through interaction with mutant p53.

Oncogene

Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, Morita KI, Oikawa Y, Harada H, Ikeda T, Thomas SM, Diaz FJ, Iwakuma T.
PMID: 34183772
Oncogene. 2021 Aug;40(31):5013-5025. doi: 10.1038/s41388-021-01921-3. Epub 2021 Jun 28.

Accumulation of mutant p53 (mutp53) is crucial for its oncogenic gain of function activity. DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to prevent unfolded mutp53 from proteasomal degradation. However, the biological function...

Cite
Kaida A, Yamamoto S, Parrales A, et al. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021;40(31):5013-5025doi: 10.1038/s41388-021-01921-3.
Kaida, A., Yamamoto, S., Parrales, A., Young, E. D., Ranjan, A., Alalem, M. A., Morita, K. I., Oikawa, Y., Harada, H., Ikeda, T., Thomas, S. M., Diaz, F. J., & Iwakuma, T. (2021). DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene, 40(31), 5013-5025. https://doi.org/10.1038/s41388-021-01921-3
Kaida, Atsushi, et al. "DNAJA1 promotes cancer metastasis through interaction with mutant p53." Oncogene vol. 40,31 (2021): 5013-5025. doi: https://doi.org/10.1038/s41388-021-01921-3
Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, Morita KI, Oikawa Y, Harada H, Ikeda T, Thomas SM, Diaz FJ, Iwakuma T. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021 Aug;40(31):5013-5025. doi: 10.1038/s41388-021-01921-3. Epub 2021 Jun 28. PMID: 34183772.
Copy Download .nbib Format: NLM
Generation of Mitochondrial-nuclear eXchange Mice via Pronuclear Transfer.

Bio-protocol

Kesterson RA, Johnson LW, Lambert LJ, Vivian JL, Welch DR, Ballinger SW.
PMID: 27840835
Bio Protoc. 2016 Oct 20;6(20). doi: 10.21769/BioProtoc.1976.

The mitochondrial paradigm for common disease proposes that mitochondrial DNA (mtDNA) sequence variation can contribute to disease susceptibility and progression. To test this concept, we developed the Mitochondrial-nuclear eXchange (MNX) model, in which isolated embryonic pronuclei from one strain...

Cite
Kesterson RA, Johnson LW, Lambert LJ, et al. Generation of Mitochondrial-nuclear eXchange Mice via Pronuclear Transfer. Bio Protoc. 2016;6(20)doi: 10.21769/BioProtoc.1976.
Kesterson, R. A., Johnson, L. W., Lambert, L. J., Vivian, J. L., Welch, D. R., & Ballinger, S. W. (2016). Generation of Mitochondrial-nuclear eXchange Mice via Pronuclear Transfer. Bio-protocol, 6(20), . https://doi.org/10.21769/BioProtoc.1976
Kesterson, Robert A, et al. "Generation of Mitochondrial-nuclear eXchange Mice via Pronuclear Transfer." Bio-protocol vol. 6,20 (2016). doi: https://doi.org/10.21769/BioProtoc.1976
Kesterson RA, Johnson LW, Lambert LJ, Vivian JL, Welch DR, Ballinger SW. Generation of Mitochondrial-nuclear eXchange Mice via Pronuclear Transfer. Bio Protoc. 2016 Oct 20;6(20). doi: 10.21769/BioProtoc.1976. PMID: 27840835; PMCID: PMC5100744.
Copy Download .nbib Format: NLM
Combustible cigarette use and other risky behavior by adult e-cigarette users in a 2019 survey.

Drug and alcohol dependence

Fox AT, Jarmolowicz DP, Reed DD, Naude GP, Martin LE.
PMID: 33032065
Drug Alcohol Depend. 2020 Nov 01;216:108324. doi: 10.1016/j.drugalcdep.2020.108324. Epub 2020 Sep 28.

No abstract available.

Cite
Fox AT, Jarmolowicz DP, Reed DD, et al. Combustible cigarette use and other risky behavior by adult e-cigarette users in a 2019 survey. Drug Alcohol Depend. 2020;216:108324doi: 10.1016/j.drugalcdep.2020.108324.
Fox, A. T., Jarmolowicz, D. P., Reed, D. D., Naude, G. P., & Martin, L. E. (2020). Combustible cigarette use and other risky behavior by adult e-cigarette users in a 2019 survey. Drug and alcohol dependence, 216108324. https://doi.org/10.1016/j.drugalcdep.2020.108324
Fox, Andrew T, et al. "Combustible cigarette use and other risky behavior by adult e-cigarette users in a 2019 survey." Drug and alcohol dependence vol. 216 (2020): 108324. doi: https://doi.org/10.1016/j.drugalcdep.2020.108324
Fox AT, Jarmolowicz DP, Reed DD, Naude GP, Martin LE. Combustible cigarette use and other risky behavior by adult e-cigarette users in a 2019 survey. Drug Alcohol Depend. 2020 Nov 01;216:108324. doi: 10.1016/j.drugalcdep.2020.108324. Epub 2020 Sep 28. PMID: 33032065.
Copy Download .nbib Format: NLM
Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design.

The American statistician

Karanevich A, Meier R, Graw S, McGlothlin A, Gajewski B.
PMID: 32981939
Am Stat. 2019;2019. doi: 10.1080/00031305.2019.1610065. Epub 2019 Jun 24.

When a researcher desires to test several treatment arms against a control arm, a two-stage adaptive design can be more efficient than a single-stage design where patients are equally allocated to all treatment arms and the control. We see...

Cite
Karanevich A, Meier R, Graw S, et al. Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design. Am Stat. 2019;2019doi: 10.1080/00031305.2019.1610065.
Karanevich, A., Meier, R., Graw, S., McGlothlin, A., & Gajewski, B. (2019). Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design. The American statistician, 2019. https://doi.org/10.1080/00031305.2019.1610065
Karanevich, Alex, et al. "Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design." The American statistician vol. 2019 (2019). doi: https://doi.org/10.1080/00031305.2019.1610065
Karanevich A, Meier R, Graw S, McGlothlin A, Gajewski B. Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design. Am Stat. 2019;2019. doi: 10.1080/00031305.2019.1610065. Epub 2019 Jun 24. PMID: 32981939; PMCID: PMC7517602.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 75 entries